Translation and Validation of MPCOSQ in Urdu Language

Riphah International University

Status: Completed

Conditions: PCOS- Polycystic Ovary Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT05010551

REC/00843 Rabbiya Zaman

Details and patient eligibility

About

To translate and validate modifies polycystic ovary syndrome quality of life (MPCOQ) questionnaire into Urdu. To evaluate the reliability, validity and of Urdu version of modified polycystic ovary syndrome quality of life questionnaire (MPCOQ).

Full description

• All statistical analyses will be conducted using the Statistical Product and Service Solution version 21 software.
• Continuous variables will be shown by mean and standard deviation and the categories will be demonstrated in frequency and percentage.
• In this study, factor structure of the (MPCOQ) will be analyzed using the principal component factor analysis with varimax rotation.
• Intraclass Correlation Coefficient (ICC) (95% confidence interval) will be used for test-retest value and Cronbach's Alpha will be used for internal consistency analysis.
• Measurement error will be determined by calculating the standard error of measurement (SEM) and the Smallest Detectable Change (SDC). Independent t-test will be used to determine the differences between groups

Enrollment: 180 patients

Sex: Female

Ages: 18 to 30 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Age 18 - 30

  • Married
  • Female patients diagnosed with PCOS, having 2 of the following Rotterdam diagnostic criteria:

I. Polycystic ovaries visualized on ultrasound scan (presence of 12 follicles or more in one or both ovaries and/or increased ovarian volume >10ml II. Clinical signs of hyperandrogenism (the hirsutism score based on the Ferriman-Gallwey score >7 or obvious acne) III. Having an interval between menstrual periods >35 days and/or amenorrhea as the absence of vaginal bleeding for at least 6 months, i.e. 199 days Patients who are willing to participate

Exclusion criteria

• • Non-adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia

  • Female undergoing Hormone Replacement Therapy
  • Female with malignancies
  • Any recent fractures, surgeries
  • Patient with nephrological and neurological conditions
  • Dementia or cognitive impairments